Orchestra BioMed Holdings, Inc. Cash Flow Statement
OBIO|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$51M
FY2025
Free Cash Flow
-$51M
FY2025
Capital Expenditures
$289,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Orchestra BioMed Holdings, Inc. used $51M in operating cash flow and negative free cash flow of $51M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$61.0M | -$49.1M | -$33.6M |
| Depreciation & Amortization | $308.0K | $287.0K | $222.0K |
| Operating Cash Flow | -$50.6M | -$46.1M | -$29.3M |
| Capital Expenditures | $289.0K | $78.0K | $591.0K |
| Free Cash Flow | -$50.8M | -$46.2M | -$29.9M |
| FCF Margin | -1927.5% | -1674.1% | -845.7% |